Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov;131(12):1630-1639.
doi: 10.1111/1471-0528.17871. Epub 2024 May 29.

In utero aspirin exposure and child neurocognitive development: A propensity score-matched analysis

Jing Zhu  1   2 , Yuexin Gan  1   2 , Cuiping Yang  1   2 , Wei Gu  1   2 , Yanlin Wang  1   2 , Jun Zhang  1   3 , Zhiwei Liu  1   2
Affiliations
Multicenter Study

In utero aspirin exposure and child neurocognitive development: A propensity score-matched analysis

Jing Zhu et al. BJOG. 2024 Nov.

Abstract

Objective: To evaluate the association between a short-period, high-dose in utero aspirin exposure and child neurocognitive development.

Design: A propensity score-matched analysis of a multicentre prospective cohort study.

Setting: The US Collaborative Perinatal Project (1959-1976).

Population: A total of 50 565 singleton live births with maternal information.

Methods: We performed a propensity score matching to balance maternal characteristics between women with and without aspirin exposure. Inverse probability-weighted marginal structural models were used to estimate associations between aspirin exposure and child neurocognitive assessments.

Main outcome measures: Child neurocognitive development was assessed using the Bayley Scales at 8 months, the Stanford Binet Intelligence Scale at 4 years, and the Wechsler Intelligence Scale and Wide-Range Achievement Test (WRAT) at 7 years.

Results: Children exposed to aspirin in utero were associated with an 8%-16% reduced risk of having suspect/abnormal or below-average scores in most neurocognitive assessments. A trend of lower risks of having suspect/abnormal or below-average scores was further observed in children with in utero aspirin exposure for more than 7 days, particularly on Bayley Mental (relative risk [RR] 0.82, 95% CI 0.74-0.92), WRAT Reading (RR 0.88, 95% CI 0.78-0.98) and WRAT Arithmetic tests (RR 0.76, 95% CI 0.66-0.86). This association was mainly observed in the second trimester of pregnancy.

Conclusions: In utero aspirin exposure was associated with improved child neurocognitive development in a prospective cohort study. Further studies are warranted to evaluate the impact of long-period and low-dose in utero aspirin exposure on child short- and long-term neurodevelopment.

Keywords: antenatal exposure; aspirin; neurocognitive development; propensity score matching.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
    1. Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019(10):CD004659.
    1. Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al. Low‐dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double‐blind, placebo‐controlled trial. Lancet. 2020;395(10220):285–293.
    1. Kupka E, Hesselman S, Hastie R, Lomartire R, Wikström AK, Bergman L. Low‐dose aspirin use in pregnancy and the risk of preterm birth: a Swedish register‐based cohort study. Am J Obstet Gynecol. 2023;228(3):336.e1–336.e9.
    1. Lim S, McDougall ARA, Goldstein M, Tuttle A, Hastie R, Tong S, et al. Analysis of a maternal health medicines pipeline database 2000–2021: new candidates for the prevention and treatment of fetal growth restriction. BJOG. 2023;130(6):653–663.

Publication types

Substances